Compare

Two terms, side by side

Pick any two terms to see definitions, context, pitfalls, and sources in parallel.

Investment & Finance

Special Purpose Acquisition Company(SPAC)

In one line

A publicly traded shell company formed to raise capital through an IPO with the sole purpose of acquiring or merging with a private operating company.

Definition

A Special Purpose Acquisition Company (SPAC) is a publicly traded shell company that raises capital in an IPO and then has a defined window (typically 18-24 months) to identify and merge with a private operating company in a 'de-SPAC' transaction. Several MedTech companies (e.g., Butterfly Network, Owlet, 23andMe) went public via SPAC during the 2020-2021 boom. The SEC's January 2024 final rule on SPACs materially raised disclosure and gatekeeper liability standards, dampening the market.

Why it matters

Post-2024, SPACs are no longer a faster or cheaper path to public markets for most MedTech companies. Many de-SPAC MedTechs traded poorly post-merger, reshaping investor appetite.

Common pitfalls

•Treating projections in the de-SPAC proxy as marketing rather than as Section 11 liability exposure.

Sources

SEC — SPAC Final Rule (2024) · SEC
SEC Final Rule 33-11265 — SPACs, Shell Companies, and Projections · SEC
NVCA Model Documents · NVCA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.